Vitality Watch

Dossier pubmed preclinical 13-jul-2026
Animal model, organoid, or cell-culture result — not yet human

HMGCR-Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence.

Key claim: HMGCR-driven cholesterol biosynthesis promotes osteoarthritis progression by accelerating synovial fibroblast senescence, and targeted HMGCR inhibition reverses FLS senescence, synovitis, cartilage loss, and pain in OA mice.

Abstract

Dysregulated cholesterol metabolism has been implicated in several aging-associated disorders, including osteoarthritis (OA). 3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) is the key enzyme in cholesterol biosynthesis, but the role of HMGCR in OA and the underlying mechanism remain unclear. In this study, we found that HMGCRfibroblasts (FLSs) were significantly increased in the knee synovium of OA patients and OA mice. Elevated expression of HMGCR in synovial FLSs was positively correlated with cellular senescence and OA progression. The inhibition of HMGCR reversed cellular senescence of FLSs induced by TNF-α in vitro. Additionally, the HMGCR-mediated cholesterol biosynthetic pathway contributed to cellular senescence. Targeted inhibition of HMGCR in synovial FLSs via intra-articular adeno-associated virus delivery effectively reversed cellular senescence of FLSs and mitigated synovitis, cartilage degradation, and pain behaviors in OA mice. Mechanistically, the phosphorylation of AKT1 at Ser473 enhanced its binding to Lys140 of Insig1, facilitating AKT1-Insig1 complex formation. The activation of AKT1 induced the phosphorylation of Insig1 at Ser189 and the dissociation of Insig1 from sterol regulatory element‑binding protein cleavage‑activating protein (SCAP), which contributed to HMGCR transcription and cellular senescence of FLSs. Collectively, our study reveals a novel mechanism of HMGCR-driven cellular senescence of FLSs in OA, which highlights HMGCR as a promising therapeutic target for OA.

Why this matters

This finding threads cholesterol biosynthesis directly into the senescence program via an AKT1–Insig1–SCAP–HMGCR axis in synovial fibroblasts, extending the causal picture beyond DDR/telomere/SASP-centric triggers to a druggable metabolic node already targeted clinically by statins. It reframes osteoarthritis as a joint-tissue senescence disorder with a specific metabolic driver, and creates a mechanistic bridge between lipid metabolism and cellular senescence that will need human validation before any repurposing narrative holds.

Source

Link

Briefing card

HMGCR-Driven Cholesterol Metabolism Promotes Osteoarthritis Progression by Accelerating Synovial Fibroblast Senescence.
Stage: preclinical · pubmed · 13-jul-2026

HMGCR-driven cholesterol biosynthesis promotes osteoarthritis progression by accelerating synovial fibroblast senescence, and targeted HMGCR inhibition reverses FLS senescence, synovitis, cartilage loss, and pain in OA mice.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: doi:10.1002/advs.76498

build build 880 · 2bcef25 · 2026-11-18